Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Circ Res. 2019 Feb;124(3):437–450. doi: 10.1161/CIRCRESAHA.118.313129

Figure 3. Efficacy of Achieving the “Dual Goals” of LDL and hsCRP Reduction.

Figure 3.

Best cardiovascular outcomes are achieved among atherosclerosis patients treated with statin therapy (left, PROVE-IT) or with statin therapy plus ezetimibe (right, IMPROVE-IT) who not only lowered LDLC below 70mg/dL but who also lowered hsCRP below 2mg/L. Data from Ridker et al, N Engl J Med 2005; 352:20–8 and Bohula et al Circulation 2015; 132:1224–33.